These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 1914339

  • 1. Clinical pharmacokinetics of propafenone.
    Hii JT, Duff HJ, Burgess ED.
    Clin Pharmacokinet; 1991 Jul; 21(1):1-10. PubMed ID: 1914339
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Propafenone: a new antiarrhythmic agent.
    Chow MS, Lebsack C, Hilleman D.
    Clin Pharm; 1988 Dec; 7(12):869-77. PubMed ID: 3061720
    [Abstract] [Full Text] [Related]

  • 4. Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
    Bryson HM, Palmer KJ, Langtry HD, Fitton A.
    Drugs; 1993 Jan; 45(1):85-130. PubMed ID: 7680987
    [Abstract] [Full Text] [Related]

  • 5. Propafenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Harron DW, Brogden RN.
    Drugs; 1987 Dec; 34(6):617-47. PubMed ID: 3322781
    [Abstract] [Full Text] [Related]

  • 6. An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
    Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M.
    Circulation; 1994 May; 89(5):2396-400. PubMed ID: 7910120
    [Abstract] [Full Text] [Related]

  • 7. Stereoselective steady state disposition and action of propafenone in Chinese subjects.
    Li G, Gong PL, Qiu J, Zeng FD, Klotz U.
    Br J Clin Pharmacol; 1998 Nov; 46(5):441-5. PubMed ID: 9833596
    [Abstract] [Full Text] [Related]

  • 8. Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies.
    Stoschitzky K, Klein W, Stark G, Stark U, Zernig G, Graziadei I, Lindner W.
    Clin Pharmacol Ther; 1990 Jun; 47(6):740-6. PubMed ID: 2162749
    [Abstract] [Full Text] [Related]

  • 9. [Significance of the degree of oxidative hepatic metabolism in conditioning the pharmacokinetics and the pharmacodynamics of propafenone].
    Boriani G, Capucci A, Strocchi E, Marchesini B, Baroni M, Frabetti L, Ambrosioni E, Magnani B.
    G Ital Cardiol; 1991 May; 21(5):517-26. PubMed ID: 1936756
    [Abstract] [Full Text] [Related]

  • 10. Clinical pharmacology and beta-blocking efficacy of propafenone.
    Barbey JT.
    J Cardiovasc Pharmacol; 1991 May; 17 Suppl 6():S41-3. PubMed ID: 1723117
    [Abstract] [Full Text] [Related]

  • 11. Comparative pharmacokinetics and clinical pharmacology of propafenone enantiomers after oral administration to man.
    Brode E, Müller-Peltzer H, Hollmann M.
    Methods Find Exp Clin Pharmacol; 1988 Nov; 10(11):717-27. PubMed ID: 3221745
    [Abstract] [Full Text] [Related]

  • 12. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.
    Groschner K, Lindner W, Schnedl H, Kukovetz WR.
    Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837
    [Abstract] [Full Text] [Related]

  • 13. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK, Fischer C, Meese CO, Eichelbaum M.
    Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations.
    Siddoway LA, Roden DM, Woosley RL.
    Am J Cardiol; 1984 Nov 14; 54(9):9D-12D. PubMed ID: 6496371
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of propafenone enantiomers in rats.
    Mehvar R.
    Drug Metab Dispos; 1990 Nov 14; 18(6):987-91. PubMed ID: 1981549
    [Abstract] [Full Text] [Related]

  • 16. Interaction between digoxin and propafenone.
    Calvo MV, Martin-Suarez A, Martin Luengo C, Avila C, Cascon M, Domínguez-Gil Hurlé A.
    Ther Drug Monit; 1989 Nov 14; 11(1):10-5. PubMed ID: 2911842
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic and pharmacodynamic interactions of propafenone and cimetidine.
    Pritchett EL, Smith WM, Kirsten EB.
    J Clin Pharmacol; 1988 Jul 14; 28(7):619-24. PubMed ID: 3063727
    [Abstract] [Full Text] [Related]

  • 18. [Determination of oxidative phenotype in a sample population and correlation with the pharmacokinetics of propafenone].
    Boriani G, Strocchi E, Capucci A, Boschi S, Frabetti L, Ambrosioni E, Magnani B.
    Cardiologia; 1990 Feb 14; 35(2):163-9. PubMed ID: 2208201
    [Abstract] [Full Text] [Related]

  • 19. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.
    Lee JT, Kroemer HK, Silberstein DJ, Funck-Brentano C, Lineberry MD, Wood AJ, Roden DM, Woosley RL.
    N Engl J Med; 1990 Jun 21; 322(25):1764-8. PubMed ID: 1971708
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration.
    Giani P, Landolina M, Giudici V, Bianchini C, Ferrario G, Marchi S, Riva E, Latini R.
    Eur J Clin Pharmacol; 1988 Jun 21; 34(2):187-94. PubMed ID: 3383990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.